oxybutynin has been researched along with Allodynia in 6 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the effects of topical lidocaine on skin sensation and on intradermal capsaicin-induced pain and hyperalgesia." | 9.15 | Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. ( Lam, VY; Schulteis, G; Wallace, M, 2011) |
| "3°C cold water), nerve growth factor-induced muscle soreness and intradermal capsaicin-induced hyperalgesia and allodynia." | 9.15 | Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. ( Andresen, T; Arendt-Nielsen, L; Christrup, LL; Drewes, AM; Foster, DJ; Upton, RN, 2011) |
| "A prospective, open-label, observational study in patients with postherpetic neuralgia, posttraumatic or postsurgical nerve injury, HIV-associated distal sensory polyneuropathy, or other peripheral neuropathic pain, and average daily pain score ≥4, who received ≤6 capsaicin 8% patch treatments over 52 weeks according to clinical need (retreatment at 9 to 12 wk intervals)." | 5.24 | Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety Study. ( Attal, N; Ernault, E; Gálvez, R; Maihöfner, C; Moyle, G; Navez, ML; Nurmikko, TJ; Stoker, M, 2017) |
| "Topical lidocaine (5%) leads to sufficient pain relief in only 29%-80% of treated patients, presumably by small-fiber block." | 5.16 | Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers. ( Krumova, EK; Maier, C; Westermann, A; Zeller, M, 2012) |
| "This study evaluated the effects of topical lidocaine on skin sensation and on intradermal capsaicin-induced pain and hyperalgesia." | 5.15 | Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. ( Lam, VY; Schulteis, G; Wallace, M, 2011) |
| "3°C cold water), nerve growth factor-induced muscle soreness and intradermal capsaicin-induced hyperalgesia and allodynia." | 5.15 | Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. ( Andresen, T; Arendt-Nielsen, L; Christrup, LL; Drewes, AM; Foster, DJ; Upton, RN, 2011) |
| " The capsaicin 8% patch is a Food and Drug Administration-approved treatment of neuropathic pain in postherpetic neuralgia and has demonstrated significant efficacy in human immunodeficiency virus-autonomic neuropathy." | 3.81 | Capsaicin 8% Patch for Central and Peripheral Neuropathic Pain of Persons with Incomplete Spinal Cord Injury: Two Case Reports. ( Trbovich, M; Yang, H, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gálvez, R | 1 |
| Navez, ML | 1 |
| Moyle, G | 1 |
| Maihöfner, C | 1 |
| Stoker, M | 1 |
| Ernault, E | 1 |
| Nurmikko, TJ | 1 |
| Attal, N | 1 |
| Madsen, CS | 1 |
| Johnsen, B | 1 |
| Fuglsang-Frederiksen, A | 1 |
| Jensen, TS | 1 |
| Finnerup, NB | 1 |
| Trbovich, M | 1 |
| Yang, H | 1 |
| Lam, VY | 1 |
| Wallace, M | 1 |
| Schulteis, G | 1 |
| Andresen, T | 1 |
| Upton, RN | 1 |
| Foster, DJ | 1 |
| Christrup, LL | 1 |
| Arendt-Nielsen, L | 1 |
| Drewes, AM | 1 |
| Krumova, EK | 1 |
| Zeller, M | 1 |
| Westermann, A | 1 |
| Maier, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for oxybutynin and Allodynia
| Article | Year |
|---|---|
Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety Study.
Topics: Aged; Analgesics, Non-Narcotic; Capsaicin; Female; Humans; Hyperalgesia; Male; Middle Aged; Neuralgi | 2017 |
Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial.
Topics: Anesthetics, Local; Capsaicin; Double-Blind Method; Humans; Hyperalgesia; Injections, Intradermal; L | 2011 |
Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Capsaicin; Cold Temperature; Cross-Over Studies; Dose-Resp | 2011 |
Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers.
Topics: Adult; Aged; Anesthetics, Local; Double-Blind Method; Female; Humans; Hyperalgesia; Lidocaine; Male; | 2012 |
2 other studies available for oxybutynin and Allodynia
| Article | Year |
|---|---|
Differential effects of a 5% lidocaine medicated patch in peripheral nerve injury.
Topics: Adult; Anesthetics, Local; Evoked Potentials; Female; Humans; Hyperalgesia; Lidocaine; Male; Middle | 2013 |
Capsaicin 8% Patch for Central and Peripheral Neuropathic Pain of Persons with Incomplete Spinal Cord Injury: Two Case Reports.
Topics: Adult; Aged; Capsaicin; Humans; Hyperalgesia; Male; Neuralgia; Pain Measurement; Sensory System Agen | 2015 |